Literature DB >> 28120185

Drug Therapy for Stable Angina Pectoris.

Talla A Rousan1, Sunil T Mathew1, Udho Thadani2.   

Abstract

Chronic stable angina pectoris refers to the predictable, reproducible occurrence of pressure or a choking sensation in the chest or adjacent areas caused by myocardial ischemia in association with physical or emotional stress, and cessation of exertion and or sublingual nitroglycerin invariably relieves the discomfort. It is a common presenting symptom of severe narrowing of one or more coronary arteries, non-obstructive coronary arteries, or even when the coronary arteries are angiographically normal. Patients often avoid activities which precipitate symptoms and have impaired quality of life. Most patients with angina pectoris can be managed with lifestyle changes, especially abstinence from smoking and regular exercise, and anti-anginal drugs. However, the choice of initial or combination antianginals as recommended in the guidelines is not evidence based. In addition, patients with stable angina due to coronary artery disease should also receive aspirin and a statin. Treatment of patients with angina and normal coronary arteries remains to be established. The aim of this article is to provide the readers not only with a guideline-based approach, which varies from one country to another, but also an individual-based approach, which takes into consideration circulatory status and the presence or absence of comorbidities in the treatment decision-making process. This manuscript primarily deals with drug therapy of stable angina pectoris and not coronary artery revascularization, which also provides angina relief but is usually reserved for patients who fail to respond to adequate drug therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28120185     DOI: 10.1007/s40265-017-0691-7

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  140 in total

Review 1.  Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.

Authors:  Robert A Kloner
Journal:  Circulation       Date:  2004-11-09       Impact factor: 29.690

2.  Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

Authors:  Peter H Stone; Nikolay A Gratsiansky; Alexey Blokhin; I-Zu Huang; Lixin Meng
Journal:  J Am Coll Cardiol       Date:  2006-06-15       Impact factor: 24.094

3.  The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group.

Authors: 
Journal:  JAMA       Date:  1981-11-06       Impact factor: 56.272

4.  Reversible Parkinsonism linked to trimetazidine (continued).

Authors: 
Journal:  Prescrire Int       Date:  2006-08

Review 5.  Side effects of using nitrates to treat angina.

Authors:  Udho Thadani; Tiffany Rodgers
Journal:  Expert Opin Drug Saf       Date:  2006-09       Impact factor: 4.250

6.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

8.  Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.

Authors:  U Thadani; M Ezekowitz; L Fenney; Y K Chiang
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

9.  Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.

Authors:  Giora Weisz; Ramin Farzaneh-Far; Ori Ben-Yehuda; Bernard Debruyne; Gilles Montalescot; Amir Lerman; Ehtisham Mahmud; Karen P Alexander; E Magnus Ohman; Harvey D White; Ann Olmsted; Gennyne A Walker; Gregg W Stone
Journal:  Am Heart J       Date:  2013-10-16       Impact factor: 4.749

10.  Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Authors:  Kim Fox; Ian Ford; Ph Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

View more
  6 in total

1.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Relief of Ischemia in Ischemic Cardiomyopathy.

Authors:  Francesco Moroni; Zachary Gertz; Lorenzo Azzalini
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

3.  Complementary and alternative therapies for stable angina pectoris of coronary heart disease: A protocol for systematic review and network meta-analysis.

Authors:  Guanyu Wang; Feiran Li; Xu Hou
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

4.  Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation.

Authors:  Yibao Ma; Wei Wang; Teja Devarakonda; Huiping Zhou; Xiang-Yang Wang; Fadi N Salloum; Sarah Spiegel; Xianjun Fang
Journal:  Sci Rep       Date:  2020-01-29       Impact factor: 4.379

5.  Organic mononitrites of 1,2-propanediol act as an effective NO-releasing vasodilator in pulmonary hypertension and exhibit no cross-tolerance with nitroglycerin in anesthetized pigs.

Authors:  Kristofer F Nilsson; Waldemar Goździk; Claes Frostell; Stanisław Zieliński; Marzena Zielińska; Kornel Ratajczak; Piotr Skrzypczak; Sylwia Rodziewicz; Johanna Albert; Lars E Gustafsson
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

6.  The Clinical Efficacy of Phytochemical Medicines Containing Tanshinol and Ligustrazine in the Treatment of Stable Angina: A Systematic Review and Meta-Analysis.

Authors:  Li Gao; Tong Wu; Juan Wang; Zhuoran Xiao; Chunhua Jia; Wei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-02       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.